Literature DB >> 10844052

Open-angle glaucoma associated with Graves disease.

K Ohtsuka1, Y Nakamura.   

Abstract

PURPOSE: To estimate the prevalence of open-angle glaucoma, including normal-tension glaucoma, in association with Graves disease.
METHODS: In a prospective study, a complete ophthalmic examination including applanation tonometry, exophthalmometry, automated static threshold perimetry, and computed tomography of the orbit was performed in 104 consecutive Japanese patients with Graves disease (age range, 11 to 86 years; mean, 42 years; 80 women, 24 men). Ocular hypertension was defined as an intraocular pressure greater than 21 mm Hg on at least two occasions during the period of follow-up.
RESULTS: Of the 104 patients, 14 (13%) exhibited typical glaucomatous visual field defects in automatic static threshold perimetry in the absence of compressive optic neuropathy. The intraocular pressure in seven of the 14 patients was consistently less than 21 mm Hg during the follow-up period. Thus, these patients were diagnosed as having normal-tension glaucoma. Of the 104 patients, 23 (22%) were diagnosed as having ocular hypertension.
CONCLUSIONS: The prevalence of normal-tension glaucoma as well as open-angle glaucoma and ocular hypertension was significantly higher among patients with Graves disease than in the general population.

Entities:  

Mesh:

Year:  2000        PMID: 10844052     DOI: 10.1016/s0002-9394(99)00473-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.

Authors:  David B Granet; Nickisa Hodgson; Kyle J Godfrey; Ricardo Ventura; Don O Kikkawa; Leah Levi; Michael Kinori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-10       Impact factor: 3.117

2.  Hyperthyroid vs hypothyroid eye disease: the same severity and activity.

Authors:  M B Kashkouli; F Pakdel; V Kiavash; I Heidari; A Heirati; S Jam
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

3.  Intraocular pressure and superior ophthalmic vein blood flow velocity in Graves' orbitopathy: relation with the clinical features.

Authors:  Onur Konuk; Zafer Onaran; Suna Ozhan Oktar; Cem Yucel; Mehmet Unal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-16       Impact factor: 3.117

4.  The association between thyroid problems and glaucoma.

Authors:  J M Cross; C A Girkin; C Owsley; G McGwin
Journal:  Br J Ophthalmol       Date:  2008-10-16       Impact factor: 4.638

5.  Hyperthyroid patients without Graves' orbitopathy are not at increased risk of developing glaucoma: a nationwide Danish register-based case-control study.

Authors:  F Brandt; M Thvilum; L Hegedüs; T H Brix
Journal:  Endocrine       Date:  2017-12-02       Impact factor: 3.633

6.  Biometric and refractive changes after orbital decompression in Korean patients with thyroid-associated orbitopathy.

Authors:  W S Kim; Y S Chun; B Y Cho; J K Lee
Journal:  Eye (Lond)       Date:  2015-11-20       Impact factor: 3.775

7.  Glaucomatous Optic Nerve Changes and Thyroid Dysfunction in an Urban South Korean Population.

Authors:  Yu Sam Won; Da Yeong Kim; Joon Mo Kim
Journal:  J Ophthalmol       Date:  2017-05-02       Impact factor: 1.909

8.  The Effect of Inferior Rectus Muscle Thickening on Intraocular Pressure in Thyroid-Associated Ophthalmopathy.

Authors:  Xiuhong Li; Xu Bai; Zhibin Liu; Ming Cheng; Jia Li; Nian Tan; Hongfeng Yuan
Journal:  J Ophthalmol       Date:  2021-01-29       Impact factor: 1.909

9.  Optimization of orbital retraction during endoscopic transorbital approach via quantitative measurement of the intraocular pressure - [SevEN 006].

Authors:  Woohyun Kim; Ju Hyung Moon; Eui Hyun Kim; Chang-Ki Hong; Jisang Han; Je Beom Hong
Journal:  BMC Ophthalmol       Date:  2021-02-08       Impact factor: 2.209

10.  Topical Treatment of Elevated Intraocular Pressure in Patients with Graves' Orbitopathy.

Authors:  Magdalena Gumińska; Roman Goś; Janusz Śmigielski; Michał S Nowak
Journal:  Int J Environ Res Public Health       Date:  2020-12-13       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.